A Systematic Review and Aggregated Analysis on the Impact of Amyloid PET Brain Imaging on the Diagnosis, Diagnostic Confidence, and Management of Patients being Evaluated for Alzheimer’s Disease
Open accessAbstract
Background: Amyloid PET (aPET) imaging could improve patient outcomes in clinical practice, but the extent of impact needs quantification. Objective: To provide an aggregated quantitative analysis of the value added by aPET in cognitively impaired subjects. Methods: Systematic literature searches were performed in Embase and Medline until January 2017. 1,531 cases over 12 studies were included (1,142 cases over seven studies in the primary analysis where aPET was the key biomarker; the remaining cases included as defined groups in the secondary analysis). Data was abstracted by consensus among two observers and assessed for bias. Clinical utility was measured by diagnostic change, diagnostic confidence, and patient management before and after aPET. Three groups were further analyzed: control patients for whom feedback of aPET scan results was delayed; aPET Appropriate Use Criteria (AUC+) cases; and patients undergoing additional FDG/CSF testing. Results: For 1,142 cases with only aPET, 31.3% of diagnoses were revised, whereas 3.2% of diagnoses changed in the delayed aPET control group ( p < 0.0001). Increased diagnostic confidence following aPET was found for 62.1% of 870 patients. Management changes with aPET were found in 72.2% of 740 cases and in 55.5% of 299 cases in the control group ( p < 0.0001). The diagnostic value of aPET in AUC+ patients or when FDG/CSF were additionally available did not substantially differ from the value of aPET alone in the wider population. Conclusions: Amyloid PET contributed to diagnostic revision in almost a third of cases and demonstrated value in increasing diagnostic confidence and refining management plans.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
PET imaging has utility for diagnostic decision making, confidence in diagnosis and management planning for patients with cognitive impairment.
“The PET imaging has utility of diagnostic decision making, confidence in diagnosis and management planning for patients with cognitive impairment [79].”
From Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease (2020) · cites this paper as [79]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · see citing works
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537 · see citing works
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · see citing works
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · see citing works
Whiting, P., Rutjes, A. W., Reitsma, J. B., Bossuyt, P. M., & Kleijnen, J. (2003) · BMC Medical Research Methodology · doi:10.1186/1471-2288-3-25 · Cited by 3,592 · see citing works
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321 · see citing works
Jack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.004 · Cited by 2,042 · see citing works
Systematic Reviews of Diagnostic Test Accuracy
Leeflang, M. M. G., Deeks, J. J., Gatsonis, C., & Bossuyt, P. M. M. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-12-200812160-00008 · Cited by 1,124 · see citing works
Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117 · see citing works
Beach, T. G., Monsell, S. E., Phillips, L. E., & Kukull, W. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31824b211b · Cited by 1,103 · cited 2× · see citing works
“Also, concordance between diagnostic change after aPET and extent of mismatch between clinical diagnosis and final neuropathological diagnosis [72] indicates overall high diagnostic performance of aPET.”
BackgroundArévalo-Rodríguez, I., Smailagic, N., Figuls, M. R. I., Ciapponi, A., Sanchez-Perez, E., Giannakou, A., Pedraza, O. L., Bonfill, X., & Cullum, S. J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010783.pub2 · Cited by 897 · see citing works
Clark, C. M., Pontecorvo, M. J., Beach, T. G., Bedell, B. J., Coleman, R. E., Doraiswamy, P. M., Fleisher, A. S., Reiman, E. M., Sabbagh, M. N., Sadowsky, C. H., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70142-4 · Cited by 855 · see citing works
Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies
Whiting, P. F., Weswood, M. E., Rutjes, A. W., Reitsma, J. B., Bossuyt, P. M., & Kleijnen, J. (2006) · BMC Medical Research Methodology · doi:10.1186/1471-2288-6-9 · Cited by 767 · see citing works
Johnson, K. A., Minoshima, S., Bohnen, N. I., Donohoe, K. J., Foster, N. L., Herscovitch, P., Karlawish, J. H., Rowe, C. C., Carrillo, M. C., Hartley, D. M., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.01.002 · Cited by 603 · see citing works
Timely Diagnosis for Alzheimer’s Disease: A Literature Review on Benefits and Challenges
Dubois, B., Padovani, A., Scheltens, P., Rossi, A., & Dell’Agnello, G. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150692 · Cited by 565 · see citing works
Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease
Blennow, K., Dubois, B., Fagan, A. M., Lewczuk, P., de Leon, M. J., & Hampel, H. J. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.02.004 · Cited by 455 · see citing works
Donohue, M. C., Sperling, R. A., Petersen, R., Sun, C.-K., Weiner, M. W., Aisen, P. S., & Initiative, F. T. A. D. N. (2017) · JAMA · doi:10.1001/jama.2017.6669 · Cited by 452 · see citing works
Palmqvist, S., Mattsson, N., Hansson, O., & Initiative, F. T. A. D. N. (2016) · Brain · doi:10.1093/brain/aww015 · Cited by 400 · see citing works
Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
Palmqvist, S., Zetterberg, H., Mattsson, N., Johansson, P., Initiative, F. T. A. D. N., Minthon, L., Blennow, K., Olsson, M., For the Swedish BioFINDER study group, Hansson, O., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001991 · Cited by 375 · see citing works
Palmqvist, S., Zetterberg, H., Blennow, K., Vestberg, S., Andreasson, U., Brooks, D. J., Owenius, R., Hägerström, D., Wollmer, P., Minthon, L., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1358 · Cited by 368 · see citing works
No role for quality scores in systematic reviews of diagnostic accuracy studies
Whiting, P. F., Harbord, R. M., & Kleijnen, J. (2005) · BMC Medical Research Methodology · doi:10.1186/1471-2288-5-19 · Cited by 333 · see citing works
Suspected non-Alzheimer disease pathophysiology — concept and controversy
Jack, C. R., Knopman, D. S., Chételat, G., Dickson, D. W., Fagan, A. M., Frisoni, G. B., Jagust, W. J., Mormino, E. C., Petersen, R. C., Sperling, R. A., et al. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.251 · Cited by 299 · see citing works
Morris, E., Chalkidou, A., Hammers, A., Peacock, J. L., Summers, J. A., & Keevil, S. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3228-x · Cited by 249 · see citing works
Self-citationSmailagic, N., Vacante, M., Hyde, C., Martin, S., Ukoumunne, O. C., & Sachpekidis, C. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010632.pub2 · Cited by 229 · see citing works
Rowe, C. C., Bourgeat, P., Ellis, K. A., Brown, B., Lim, Y. Y., Mulligan, R., Jones, G., Maruff, P., Woodward, M., Price, R., et al. (2013) · Annals of Neurology · doi:10.1002/ana.24040 · Cited by 222 · see citing works
Impact of molecular imaging on the diagnostic process in a memory clinic
Ossenkoppele, R., Prins, N. D., Pijnenburg, Y. A. L., Lemstra, A. W., van der Flier, W. M., Adriaanse, S. F., Windhorst, A. D., Handels, R. L. H., Wolfs, C. A. G., Aalten, P., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.07.003 · Cited by 194 · see citing works
Beta-amyloid imaging with florbetaben
Sabri, O., Seibyl, J., Rowe, C., & Barthel, H. (2015) · Clinical and translational imaging · doi:10.1007/s40336-015-0102-6 · Cited by 167 · see citing works
PET Approaches for Diagnosis of Dementia
Ishii, K. (2013) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3695 · Cited by 152 · see citing works
An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom
Getsios, D., Blume, S., Ishak, K. J., Maclaine, G., & Hernández, L. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.07.001 · Cited by 144 · see citing works
Grundman, M., Pontecorvo, M. J., Salloway, S., Doraiswamy, P. M., Fleisher, A., Sadowsky, C., Nair, A. K., Siderowf, A. D., Lu, M., Arora, A., et al. (2012) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318279d02a · Cited by 119 · see citing works
Diagnostic impact of [18F]flutemetamol PET in early-onset dementia
Zwan, M. D., Bouwman, F. H., Konijnenberg, E., van der Flier, W. M., Lammertsma, A. A., Verhey, F. R. J., Aalten, P., van Berckel, B. N. M., & Scheltens, P. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0228-4 · Cited by 118 · see citing works
Johnson, K. A., Minoshima, S., Bohnen, N. I., Donohoe, K. J., Foster, N. L., Herscovitch, P., Karlawish, J. H., Rowe, C. C., Hedrick, S., Pappas, V., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.06.001 · Cited by 108 · see citing works
Driscoll, I., Troncoso, J. C., Rudow, G., Sojkova, J., Pletnikova, O., Zhou, Y., Kraut, M. A., Ferrucci, L., Mathis, C. A., Klunk, W. E., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1025-1 · Cited by 104 · see citing works
Clinical Use and Utility of Amyloid Imaging
Barthel, H., & Sabri, O. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.185017 · Cited by 102 · see citing works
Toledo, J. B., Bjerke, M., Da, X., Landau, S. M., Foster, N. L., Jagust, W., Jack, C., Weiner, M., Davatzikos, C., Shaw, L. M., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4829 · Cited by 88 · see citing works
Salloway, S., Gamez, J. E., Singh, U., Sadowsky, C. H., Villena, T., Sabbagh, M. N., Beach, T. G., Duara, R., Fleisher, A. S., Frey, K. A., et al. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.06.001 · Cited by 87 · see citing works
Self-citationChételat, G., Ossenkoppele, R., Villemagne, V. L., Perrotin, A., Landeau, B., Mézenge, F., Jagust, W. J., Dore, V., Miller, B. L., Egret, S., et al. (2016) · Brain · doi:10.1093/brain/aww159 · Cited by 80 · see citing works
Willingness to Pay for Diagnostic Technologies: A Review of the Contingent Valuation Literature
Lin, P., Cangelosi, M. J., Lee, D. W., et al. (2013) · Value in Health · doi:10.1016/j.jval.2013.04.005 · Cited by 79 · see citing works
Practical utility of amyloid and FDG-PET in an academic dementia center
Sánchez‐Juan, P., Ghosh, P. M., Hagen, J., Gesierich, B. G., Henry, M. L., Grinberg, L. T., O’Neil, J. P., Janabi, M., Huang, E. J., Trojanowski, J. Q., et al. (2013) · Neurology · doi:10.1212/wnl.0000000000000032 · Cited by 78 · see citing works
A systematic review and meta‐analysis of 18F‐labeled amyloid imaging in Alzheimer's disease
Yeo, J. M., Waddell, B., Khan, Z. H., & Pal, S. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2014.11.004 · Cited by 78 · see citing works
Zhang, S., Smailagic, N., Hyde, C., Noel-Storr, A. H., Takwoingi, Y., McShane, R., & Feng, J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010386.pub2 · Cited by 66 · see citing works
Schipke, C. G., Peters, O., Heuser, I., Grimmer, T., Sabbagh, M. N., Sabri, O., Hock, C., Kunz, M., Kuhlmann, J., Reininger, C. B., et al. (2012) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000339367 · Cited by 63 · see citing works
Hatashita, S., & Yamasaki, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066877 · Cited by 57 · see citing works
Ceccaldi, M. P., Jonveaux, T., Verger, A., Krolak‐Salmon, P., Houzard, C., Godefroy, O., Shields, T., Perrotin, A., Gismondi, R., Bullich, S., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.09.009 · Cited by 56 · see citing works
Implications of early treatment among Medicaid patients with Alzheimer's disease
Geldmacher, D., Kirson, N. Y., Birnbaum, H. G., Eapen, S., Kantor, E., Cummings, A. K. G., & Joish, V. N. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.01.015 · Cited by 54 · see citing works
Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer’s disease
Adamczuk, K., Schaeverbeke, J. M., Vanderstichele, H., Lilja, J., Nelissen, N., Laere, K. V., Dupont, P. J., Hilven, K., Poesen, K., & Vandenberghe, R. R. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0159-5 · Cited by 49 · see citing works
Bensaïdane, M. R., Beauregard, J., Poulin, S. P., Buteau, F.-A., Guimond, J. V., Bergeron, D., Verret, L., Fortin, M., Houde, M., Bouchard, R. W., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151180 · Cited by 49 · see citing works
Added Diagnostic Value of 11C-PiB-PET in Memory Clinic Patients with Uncertain Diagnosis
Frederiksen, K. S., Hasselbalch, S. G., Hejl, A., Law, I. G., Højgaard, L. D., & Waldemar, G. (2012) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000345783 · Cited by 46 · see citing works
Black, C. M., Fillit, H. M., Xie, L., Hu, X., Kariburyo, M. F., Ambegaonkar, B. M., Başer, O., Yüce, H., & Khandker, R. K. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170518 · Cited by 46 · see citing works
Effectiveness of Florbetapir PET Imaging in Changing Patient Management
Pontecorvo, M., Siderowf, A., Dubois, B., Doraiswamy, P., Frisoni, G., Grundman, M., Nobili, F., Sadowsky, C., Salloway, S., Arora, A. K., et al. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000478007 · Cited by 44 · see citing works
Ivanoiu, A., Dricot, L., Gilis, N., Grandin, C. B. G., Lhommel, R., Quenon, L., & Hanseeuw, B. J. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140651 · Cited by 42 · see citing works
Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimer’s disease
Lee, S. A. W., Sposato, L. A., Hachinski, V., & Cipriano, L. E. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0243-0 · Cited by 35 · see citing works
Moulin-Romsee, G., Maes, A., Silverman, D. H. S., Mortelmans, L., & Laere, K. V. (2005) · European Journal of Neurology · doi:10.1111/j.1468-1331.2004.00940.x · Cited by 34 · see citing works
Mitsis, E. M., Bender, H. A., Kostakoğlu, L., Macháč, J., Martin, J. K., Woehr, J., Sewell, M. C., Aloysi, A. S., Goldstein, M. A., Li, C., et al. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-10 · Cited by 34 · see citing works
Weston, P. S. J., Paterson, R. W., Dickson, J. C., Barnes, A., Bomanji, J. B., Kayani, I. A., Lunn, M. P., Mummery, C. J., Warren, J. D., Rossor, M. N., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160302 · Cited by 24 · see citing works
Flagged first, then by citations
Research works printed but not linked: 5
- [18]Bloudek LM, Spackman DE, Blankenburg M, Sullivan SD, Pharma H (2014) Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer’s disease. J Alzheimers Dis 26, 627– 645. 21694448
- [20]Ritchie C, Smailagic N, Ec L, Ah N, Ukoumunne O, Martin S (2013) CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 3, CD010803. PMC6464349 28328043
- [33]Boccardi M, Altomare D, Ferrari C, Festari C, Guerra UP, Paghera B, Pizzocaro C, Lussignoli G, Geroldi C, Zanetti O, Cotelli MS, Turla M, Borroni B, Rozzini L, Mirabile D, Defanti C, Gennuso M, Prelle A, Gentile S, Morandi A, Vollaro S, Volta GD, Bianchetti A, Conti MZ, Cappuccio M, Carbone P, Bellandi D, Abruzzi L, Bettoni L, Villani D, Raimondi MC, Lanari A, Ciccone A, Facchi E, Fazio I Di, Rozzini R, Boffelli S, Manzoni L, Salvi G Pietro, Cavaliere S, Belotti G, Avanzi S, Pasqualetti P, Muscio C, Padovani A (2016) Assessment of the incremental diagnostic value of Florbetapir F 18 imaging in patients with cognitive impairment: The incremental diagnostic value of amyloid PET with [ 18F]-Florbetapir (INDIA-FBP) Study. JAMA Neurol 256, 184– 192. 27802513
- [49]Clifford RJJ, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ (2013) Update on hypothetical model of Alzheimer’s disease biomarkers. Lancet Neurol 12, 207– 216. 23332364 PMC3622225
- [68]Apostolova LG, Haider J, Goukasian N, LeClair H, Chételat G, Rabinovici GD, Ringman JM, Kremen S, Restrepo L, Mendez M, Silverman D (2017) Critical appraisal of the appropriate use criteria: Effect on diagnosis and patient care. Alzheimers Dement 11, P23. PMC5198877 28054024
Cited by
Sorted by citations
Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease
Khan, S., Barve, K. H., & Kumar, M. S. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200528142429 · Cited by 820 · see citing works
“The PET imaging has utility of diagnostic decision making, confidence in diagnosis and management planning for patients with cognitive impairment [79].”
BackgroundRabinovici, G. D., Gatsonis, C., Apgar, C., Chaudhary, K., Gareen, I., Hanna, L., Hendrix, J., Hillner, B. E., Olson, C., Lesman-Segev, O. H., et al. (2019) · JAMA · doi:10.1001/jama.2019.2000 · Cited by 674 · see citing works
Chételat, G., Arbizu, J., Barthel, H., Garibotto, V., Law, I., Morbelli, S., van de Giessen, E., Agosta, F., Barkhof, F., Brooks, D. J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30314-8 · Cited by 526 · see citing works
Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia
Ismail, Z., Black, S. E., Camicioli, R., Chertkow, H., Herrmann, N., Laforce, R., Montero‐Odasso, M., Rockwood, K., Rosa‐Neto, P., Seitz, D., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12105 · Cited by 245 · see citing works
Quantification of amyloid PET for future clinical use: a state-of-the-art review
Pemberton, H. G., Collij, L. E., Heeman, F., Bollack, A., Shekari, M., Salvadó, G., Alves, I. L., Garcia, D. V., Battle, M., Buckley, C., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05784-y · Cited by 226 · see citing works
Self-citationA Promising Approach: Magnetic Nanosystems for Alzheimer’s Disease Theranostics
Chaparro, C. I. P., Simões, B. T., Borges, J. P., Castanho, M. A. R. B., Soares, P. I. P., & Neves, V. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092316 · Cited by 40 · see citing works
Conrado, D. J., Duvvuri, S., Geerts, H., Burton, J., Biesdorf, C., Ahamadi, M., Macha, S., Hather, G., Francisco Morales, J., Podichetty, J., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1782 · Cited by 21 · see citing works
- Authors
- Fantoni, E. R., Chalkidou, A., O’ Brien, J. T., Farrar, G., & Hammers, A.
- Affiliations
- GE Healthcare, Life Sciences, Amersham, UK
- King's College London (GB)
- Department of Psychiatry, University of Cambridge, UK
- Corresponding author
- Fantoni, Enrico R.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2018-04-24
- Volume
- 63
- Issue
- 2
- Pages
- 783-796
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC5929301
- OpenAlex
- W2803066492
- Cited by
- 68
- References
- 55
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 6 · 2023: 5 · 2022: 11 · 2021: 9 · 2020: 14 · 2019: 10 · 2018: 1
- FWCI
- 1.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Research Portal (King's College London) (publishedVersion, cc-by-nc)
- Apollo (University of Cambridge) (submittedVersion, cc-by-nc)
- Apollo
- Funders
- University of Cambridge
- Menzies Centre for Australian Studies, King's College London, University of London
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- amyloid PET, Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Amyloid, Brain, Humans, Positron-Emission Tomography, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
